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The potential to improve pulmonary tuberculosis (PTB) treatment outcomes with 
adjunctive immunotherapies requires investigation. L-arginine and vitamin D have 
antimycobacterial properties which render them suitable candidates. Therefore the 
Arginine and Vitamin D Adjunctive therapy in Pulmonary TB (AVDAPT) trial 
evaluates these supplements in PTB. This large trial commenced in June 2008. The 
project is run in Timika, Papua Province, Indonesia by the International Health 
Division, Menzies School of Health Research (Darwin, Australia), the National 
Institute for Health Research and Development (Ministry of Health, Indonesia), and 
the Australian National University (Canberra).  
 
Aims of this thesis were to design and commence the AVDAPT study and examine 
baseline data. Among the tested hypotheses were that exhaled nitric oxide (FENO), an 
L-arginine-derived antimycobacterial immunological mediator, would be elevated in 
PTB compared with healthy controls (HC), and inversely related to disease severity; 
secondly, that significant relationships would exist between different measures of TB 
severity. 
 
Consenting, eligible adults with smear-positive PTB were enrolled at the Timika TB 
clinic according to the protocol. Assessments included sputum microscopy, culture 
and susceptibility, X-ray, weight, pulmonary function, FENO, 6-minute walk testing 
(6MWT) and quality of life (St George‘s Respiratory Questionnaire [SGRQ]). HC 
were enrolled for a single assessment. 
 
Results from 162 TB patients and 40 HC included: (1) findings pertaining to the trial 
(development / validation of outcome measures, and establishment of locally-relevant 
reference ranges for 6MWT and SGRQ); (2) findings pertaining to improved 
understanding of TB (demonstration of relationships between clinical, physiological, 
immunological [FENO] and functional measures of disease severity), and (3) 
investigation of TB drug-resistance and HIV rates. 
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A key finding was that FENO was not elevated in TB compared with HC and was 
lower still in worse disease. These findings suggest that an impaired ability to 
generate adequate NO (e.g. in L-arginine deficiency) might contribute to host inability 
to adequately contain TB or mitigate lung pathology. These findings support the 
rationale for conducting a trial of adjunctive L-arginine in TB.  
 
New relationships were identified between sputum smear grade, X-ray, weight, 
pulmonary function, 6MWT and SGRQ. Patients with more-severe malnutrition had 
worse pulmonary function; 6MWT was independent of lung function; SGRQ results 
accurately captured people‘s perceived quality of life, correlating significantly with 
symptoms, 6MWT and pulmonary function; and sputum bacillary grade was 
significantly related to radiological extent and weight, but not to other results. These 
findings support the use of a range of outcome measures in TB trials, to provide a 
comprehensive assessment of TB severity, rather than focusing on bacteriology alone. 
 
An x-ray severity score and a clinical outcome score were created, providing valuable 
tools for use in clinical trials. Interim analysis confirmed the safety of L-arginine and 
vitamin D adjunctive therapy. Multi-drug resistant TB rates remained low in new 
cases (2.0%), but HIV-TB co-infection rates rose significantly over 5 years, creating 
major challenges.  
 
This thesis provides the basis for continuation of the AVDAPT study, produces 
original findings relating to clinico-immunological aspects of PTB, and provides 
information of major local importance to help guide TB service provision in Timika.  
 
  




6MWT   6 minute walk test 
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AFB  Acid-fast bacilli 
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NiOX FLEX  Device for measurement of exhaled nitric oxide (non-portable)  
NiOX MINO Device for measurement of exhaled nitric oxide (portable) 
NO  Nitric oxide 
NOS  Nitric Oxide synthase 
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SGRQ  St George‟s Respiratory Questionnaire 
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Th1  T helper cell Type 1 
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UV  Ultraviolet 
VCT  Voluntary counselling and testing for HIV 
WHO  World Health Organization 
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